Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PHENYLBUTAZONE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1984

Stability-indicating assay for phenylbutazone: high-performance liquid chromatographic determination of hydrazobenzene and azobenzene in degraded aqueous phenylbutazone solutions.

A high-performance liquid chromatographic method was developed for the simultaneous determination of azobenzene, hydrazobenzene, and four other decomposition products in phenylbutazone injectable formulations. Separation was achieved on a C18 column, with 0.1 M Tris-citrate buffer (pH 5.25) and acetonitrile (52:48), at a flow rate of 2 mL/min and a detection wavelength of 237 nm. Diphenylamine was used as an internal standard. The limit of quantitation is 0.5% (with respect to phenylbutazone) of each degraded product. The detectability is 2.4 X 10(-3) micrograms for azobenzene and 1.5 X 10(-3) micrograms for hydrazobenzene. The limit of quantitation may be lowered to 0.1% (with respect to phenylbutazone) for azobenzene and hydrazobenzene in the presence of the two major decomposition products, which have been determined in commercially available injectable formulations. A higher sensitivity was obtained for azobenzene using the mobile phase 0.1 M Tris-citrate buffer (pH = 5.25) and acetonitrile (40:60) with detection at 314 nm. Under these conditions, 0.025% (with respect to phenylbutazone) of azobenzene is quantitated.

Azo Compounds↗
PubMed1981

Quality control of phenylbutazone I: Analysis of phenylbutazone and decomposition products in drugs by TLC.

A modified TLC procedure for the analysis of phenylbutazone and its degradates on silica plates is reported. This method avoids phenylbutazone degradation in situ by chelating the iron of the silica plate, which allows rapid characterization with a fluorescence indicator. A selective and sensitive assay of phenylbutazone (0.025 microgram), using a chromatographic spectrophotometer, was performed on silica plates without a fluorescence indicator. Quantitative analysis of an injectable solution is outlined.

Chromatography, Thin Layer↗
PubMed1983

A double-blind comparison of phenylbutazone and suxibuzone, a prodrug of phenylbutazone, in rheumatoid arthritis.

One hundred and fifty patients with rheumatoid arthritis received suxibuzone (426 mg/day, equivalent to 300 mg of phenylbutazone), a prodrug of phenylbutazone, or phenylbutazone (300 mg/day) in a six-week double-blind comparison study. After six weeks of treatment, morning stiffness, joint symptoms, and grip strength all improved almost equally in both groups. On the other hand, the frequency and severity of side-effects, particularly of gastro-intestinal (GI) disturbances, were markedly and significantly lower in the suxibuzone group. This study indicates that some prodrugs of non-steroid anti-inflammatory drugs are useful because they have fewer side-effects.

Anti-Inflammatory Agents↗
PubMed1981

[Comparison of bumadizone-, phenylbutazone- and oxyphenbutazone-plasma levels after a single oral dose of phenylbutazone and of bumadizone, respectively (author's transl)].

Bumadizone-calcium-semihydrate and phenylbutazone were given orally to two groups (I and II) consisting of 6 persons each; plasma levels of bumadizone, phenylbutazone and oxyphenbutazone were determined over a period of 384 h. For bumadizone a plasma half-life of 6.9 h was found, maximum plasma levels were reached after 1-6 h varying from 27 to 46 microgram/ml. Phenylbutazone- and oxyphenbutazone-AUC-values were compared between the two groups.

Administration, Oral↗
PubMed1982

Quality control of phenylbutazone II: Analysis of phenylbutazone and its decomposition products in drugs by high-pressure liquid chromatography.

A rapid, sensitive, accurate, and reproducible procedure for the simultaneous separation and determination of phenylbutazone and three major degradation products is proposed using reversed-phase high-pressure liquid chromatography and UV detection. The method is approximately 20 times more sensitive than TLC and allows an accurate determination of degradation products without decomposition during the analysis.

Chromatography, High Pressure Liquid↗
PubMed1995

A supercritical fluid chromatographic method using packed columns for phenylbutazone and oxyphenbutazone in serum, and for phenylbutazone in a dosage form.

The separation of phenylbutazone (PB) and its major metabolite oxyphenbutazone (OPB) using supercritical fluid chromatography (SFC) has been investigated. The separations were studied on octadecylsilane, silica and cyano packed columns with 5% methanol in carbon dioxide as mobile phase and detection at 240 nm. The octadecylsilane column showed the most favourable chromatographic parameters for the analysis of the analytes. Recoveries of PB and OPB from spiked human serum were in the 82-83% range using solid phase extraction on an ODS cartridge. Limits of detection of the SFC assay were 0.1 microgram ml-1 for PB and 1.0 microgram ml-1 for OPB. Accuracy and precision of the method were in the 0.24-4.94% range for PB and OPB. The SFC method was directly comparable to an HPLC assay of the same analytes. The SFC method was also applied to a commercial 100 mg dosage form of PB with good recovery of PB.

Capsules↗